Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTONEL vs ATELVIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.
Treatment of Paget's disease of bone,Treatment of osteoporosis in postmenopausal women,Prevention of osteoporosis in postmenopausal women,Treatment of glucocorticoid-induced osteoporosis,Off-label: Prevention of bone metastases in some cancers
Treatment of osteoporosis in postmenopausal women,Treatment of osteoporosis in men at high risk of fracture,Treatment and prevention of glucocorticoid-induced osteoporosis,Off-label: Paget's disease of bone
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
35 mg orally once weekly on the same day each week, taken with at least 240 m L of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal elimination half-life is approximately 10 days due to prolonged bone binding and slow release; clinical suppression of bone resorption persists for weeks after discontinuation.
Not metabolized; excreted unchanged in urine.
Risedronate is not metabolized and is excreted unchanged primarily by the kidneys (<5% metabolized). No cytochrome P450 enzymes involved.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Approximately 50% of absorbed dose excreted renally unchanged; remainder eliminated via biliary/fecal routes. Renal clearance correlates with creatinine clearance.
~24% bound to plasma proteins (primarily albumin).
Approximately 99% bound to plasma proteins, primarily albumin.
Vd: 0.5-1 L/kg, indicating distribution primarily into bone and extracellular fluid.
Mean Vd is 6.2 L/kg (range 4-10 L/kg), indicating extensive distribution into bone and soft tissues.
Oral: 0.5-1% under fasting conditions (low due to poor intestinal absorption and high first-pass effect); reduced by 60-90% with food or calcium-containing beverages.
Oral bioavailability is approximately 0.7% (range 0.5-1.0%) under fasting conditions; food and calcium-containing beverages significantly reduce absorption.
Contraindicated if Cr Cl <30 m L/min. If Cr Cl 30-49 m L/min, no adjustment needed. If Cr Cl <30 m L/min, do not use.
Contraindicated in patients with Cr Cl <15 m L/min. No dose adjustment required for Cr Cl ≥15 m L/min. For Cr Cl 15-30 m L/min, use with caution due to limited data.
No dose adjustment required for mild to moderate hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C); use caution.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use caution.
Safety and efficacy not established in pediatric patients. Not recommended for use in children.
Not approved for use in pediatric patients; safety and efficacy not established in children.
No dose adjustment based on age alone. Monitor renal function. Ensure adequate calcium and vitamin D intake. Same dosing as adults.
No specific dose adjustment required. Consider potential renal impairment (assess Cr Cl) and increased risk of gastrointestinal adverse effects. Ensure adequate calcium and vitamin D intake.
None.
No FDA black box warning.
Hypocalcemia must be corrected before therapy,Esophageal irritation and potential for esophageal cancer,Renal impairment (creatinine clearance <30 m L/min) requires dose adjustment or avoidance,Osteonecrosis of the jaw (usually with cancer treatments),Atypical femur fractures with long-term use,Musculoskeletal pain
Hypocalcemia must be corrected before therapy initiation,Severe renal impairment (Cr Cl <30 m L/min): not recommended,Osteonecrosis of the jaw (ONJ) with invasive dental procedures,Atypical femur fractures with long-term use,Upper gastrointestinal adverse events (e.g., esophagitis, ulcers) if taken incorrectly,Hypersensitivity reactions including angioedema
Hypocalcemia,Inability to stand or sit upright for at least 30 minutes,Severe renal impairment (Cr Cl <30 m L/min),Hypersensitivity to risedronate or any component
Hypocalcemia,Creatinine clearance <30 m L/min,Inability to stand or sit upright for at least 30 minutes,History of esophageal disorders (e.g., stricture, achalasia)
Calcium, magnesium, iron, and aluminum (e.g., antacids) bind risedronate and reduce absorption. Separate by at least 30 minutes after taking risedronate. Avoid mineral water, dairy products, and calcium-fortified juices within 30 minutes of dosing.
Food, beverages (except plain water), and calcium supplements reduce absorption. Avoid any food or drink for at least 30 minutes after dosing. Do not take with mineral water, coffee, tea, juice, or dairy products. Calcium, iron, magnesium, or aluminum-containing antacids should be taken at a different time of day.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. Risk cannot be ruled out; use only if clearly needed. First trimester: potential for skeletal effects; second and third trimesters: risk of fetal hypocalcemia and skeletal retardation. Discontinue if pregnancy occurs.
Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second/third trimester: Potential for maternal hypocalcemia affecting fetal bone development. No adequate human studies. Risk cannot be excluded.
Unknown if excreted in human milk. M/P ratio not established. Caution advised; consider alternative treatments during breastfeeding.
Unknown: Excretion in human milk is unknown but likely low due to high protein binding and short half-life. M/P ratio not established. Use with caution in breastfeeding due to potential for bone growth suppression in infants; alternatives preferred.
No specific pharmacokinetic data during pregnancy. Dose adjustments not routinely recommended; consider discontinuation due to potential fetal risks.
No formal dose adjustments studied. Pregnancy may increase bone turnover and renal clearance, but data insufficient to recommend dose change. Use lowest effective dose only if clearly needed. Avoid during pregnancy unless benefit outweighs risk.
Actonel (risedronate) is a bisphosphonate for osteoporosis and Paget's disease. Administer on an empty stomach with plain water (not mineral water) at least 30 minutes before the first food, beverage, or other medication. Avoid in Cr Cl <30 m L/min. Monitor for hypocalcemia before treatment. Counsel on atypical femur fractures and osteonecrosis of the jaw (ONJ), especially with dental procedures.
ATELVIA (risedronate) is a bisphosphonate for osteoporosis. Must be taken on an empty stomach with plain water only, at least 30 minutes before first food, drink, or other medication. Avoid in severe renal impairment (Cr Cl <30 m L/min). Monitor for hypocalcemia before initiation. Advise patients to remain upright for 30 minutes post-dose to reduce esophageal irritation.
Take Actonel first thing in the morning with a full glass of plain water (6-8 oz) at least 30 minutes before any food, drink, or other medicine.,Do not lie down for at least 30 minutes after taking to reduce risk of esophageal irritation.,Avoid mineral water, coffee, tea, juice, or calcium-rich beverages as they can reduce absorption.,Report severe bone, joint, or muscle pain; jaw pain or numbness; or signs of hypocalcemia (muscle cramps, tingling).,Maintain adequate calcium and vitamin D intake as directed by your doctor.,If you miss a dose, skip it and resume next morning; do not take two doses on the same day.
Take ATELVIA first thing in the morning, at least 30 minutes before any food, drink, or other medications.,Swallow the tablet whole with a full glass (6-8 oz) of plain water only; do not use mineral water, coffee, tea, or juice.,Do not chew, crush, or suck the tablet; remain upright (sitting or standing) for at least 30 minutes after taking.,If you miss a dose, skip it and take the next dose the following morning; do not take two doses on the same day.,Report symptoms of esophageal irritation such as difficulty or pain with swallowing, chest pain, or heartburn.,Ensure adequate intake of calcium and vitamin D as directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTONEL vs ATELVIA, answered by our medical review team.
ACTONEL is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.. ATELVIA is a Bisphosphonate that works by Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTONEL and ATELVIA depend on the specific clinical indication. These are both Bisphosphonate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTONEL is: 35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.. The standard adult dose of ATELVIA is: 35 mg orally once weekly on the same day each week, taken with at least 240 m L of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTONEL and ATELVIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTONEL is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. Risk cannot be ruled out; use only. ATELVIA is classified as Category C. Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.